Orca Security Offers Best-in-Class Approach to Secure Cloud-Native Applications, Expanding with ThreatOptix’s Agent-Based Runtime Protection
Orca Security, the pioneer of agentless cloud security, today announced that the Orca Cloud Security Platform will include ThreatOptix’s agent-based runtime protection and enforcement for cloud-native applications, including virtual machines, containers, and Kubernetes applications. While Orca remains committed to agentless cloud security, this new capability builds on Orca's industry leadership in delivering the most comprehensive coverage and visibility across the cloud estate and offers customers a choice in how they want to secure their applications.
New capabilities from ThreatOptix, whose technology provides comprehensive Linux security with an emphasis on cloud workload protection, will enhance the runtime detection and enforcement within the Orca Cloud Security Platform. The new features in the Orca Platform will be delivered via a strategic partnership with ThreatOptix, where all agent deployments and policy management, as well as data, will be fully integrated into the Orca Platform and sold as a single platform.
Security teams have many challenges in securing modern workloads, including vulnerability management, compliance monitoring, and advanced threat detection and prevention. Orca has been solely focused on delivering best-in-breed agentless capabilities to address these concerns. Yet there are specific mission critical applications where organizations may require an agent for advanced runtime protection and enforcement.
According to Enterprise Strategy Group*, “The growing footprint of Linux-based workloads, both virtual machine instances and application containers, has become a more prominent facet of the attack surface. Because these assets are temporal, they are often not running when security analysts are conducting investigations. As such, capturing system activity with an EDR offering that is purpose-built for Linux workloads is required.”
“At Orca Security, we have a mission to continually innovate cloud security and push the limits of what’s possible to be your key partner for securing the entirety of your cloud environments now and in the future,” said Avi Shua, CEO and co-founder of Orca Security. “As we expand our Cloud Security Platform, we are strategically partnering with ThreatOptix due to their core focus on delivering runtime protection and enforcement for cloud-native applications.”
ThreatOptix was founded by Ehud (“Udi”) Shamir and Sameet Mehta. Udi co-founded the XDR pioneer SentinelOne, where Sameet served as CFO, and both bring years of experience in workload runtime protection.
“At ThreatOptix, we have focused on cloud workload protection from inception,” said Udi Shamir. “The existing EDR solutions are not optimized to address the dynamic and ephemeral nature of modern cloud-native applications that run on containers and Kubernetes. Partnering with Orca, the leader in agentless cloud security, will strengthen an already innovative solution to better address the use cases for deploying an agent for cloud workload protection.”
Upon this integration, Orca Cloud Security Platform customers will be able to immediately deploy and manage the ThreatOptix agent as well as configure policies from the Orca UI. All agent-based runtime telemetry will be fully available within the Orca Unified Data Model to ensure ease-of-use and operation.
“Many partnerships in the cybersecurity ecosystem lack a deep integration strategy. This leads to duct-taped solutions that are inefficient and lack value for their users,” said Gil Geron CPO and co-founder of Orca Security. “We believe this strategic partnership and integration will be transformative for securing the cloud in a purpose-built way to deliver a seamless solution sold under a single SKU. Once integrated, Orca customers will have a seamless experience with the agent acting similarly to a native Orca capability. The Platform will support all cloud environments secured by us today, including highly regulated environments like FedRAMP.”
To learn more about how Orca is focused on securing cloud environments and addressing cloud risks, visit the Orca Blog. Additionally, organizations interested in trialing the Orca Platform can sign up for a free, 30-day cloud risk assessment.
Availability
The integrated solution will be available in the second half of 2023.
About Orca Security
Orca Security is the pioneer of agentless cloud security that is trusted by hundreds of enterprises globally. Orca makes cloud security possible for enterprises moving to and scaling in the cloud with its patented SideScanning™ technology and Unified Data Model. The Orca Cloud Security Platform delivers the world's most comprehensive coverage and visibility of all risks across the cloud. With this continuous first-to-market innovations and expertise, the Orca Cloud Security Platform ensures security teams quickly identify and remediate risks to keep their businesses secure. Connect your first account in minutes: https://orca.security or take the free cloud risk assessment.
About ThreatOptix
ThreatOptix provides peerless server protection architected from the ground-up to defend Linux, with a technology that makes it easy for large enterprises and government agencies to detect, classify and mitigate threats with greater efficacy than any existing offering.
* ESG: The Maturation of Cloud-native Security 2021
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230221005278/en/
Contact information
Media
Emily Townsend
fama PR for Orca Security
orca@famapr.com
Kirtee Londhe Mehta
PR for ThreatOptix, Inc.
kirtee@threatoptix.ai
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Compass Pathways Announces FDA Acceptance of IND Application for PTSD and Hosts Webinar on PTSD and TRD7.1.2026 13:30:00 EET | Press release
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation, today announced that the U.S. Food and Drug Administration (FDA) has accepted its Investigational New Drug (IND) application for COMP360, enabling the initiation of a late-stage clinical trial in patients with PTSD. Compass management, along with KOL and industry leaders, will host a webinar today to discuss the company’s clinical trial plans for PTSD, as well as commercial preparations for treatment-resistant depression (TRD) from 10:00-11:30 am ET on January 7th. “PTSD is one of the most challenging mental health conditions, with approximately 13 million adults in the U.S. living with persistent symptoms and limited treatment options,” said Dr. Guy Goodwin, Chief Medical Officer at Compass Pathways. “We are pleased to advance our clinical development - the unmet need is profound, and it demands bold innovation. We believe COMP360 has the potential to tra
Stallergenes Greer Expands Venom Immunotherapy Production Capacity With Acquisition of Entomon s.r.l.7.1.2026 12:07:00 EET | Press release
Stallergenes Greer, a global leader in allergy therapeutics, today announced that it has entered into an agreement to acquire Entomon s.r.l., an Italian company specialising in the production of certified stinging-insect venom extracts, notably of the Hymenoptera order, used for the manufacture of diagnostic preparations and Venom Immunotherapy (VIT). The transaction is expected to close by the end of January. Entomon, currently recognised as the only company in Europe capable of extracting pure venom from Hymenoptera insects, produces pharmaceutical-grade insect venom using proprietary techniques (Entomon Capillary Extracted Venom®) for medical use. Through this acquisition, Stallergenes Greer bolsters its venom manufacturing capabilities and supply of raw materials for life-saving VIT treatments, whilst safeguarding patient care continuity. Hymenoptera venom allergy is the most common trigger of severe anaphylaxis in adults1. According to the EAACI guidelines on venom immunotherapy,
ARIS Announces New CEO to Lead Agentic AI-led Strategy7.1.2026 11:00:00 EET | Press release
CEO Appointment ARIS, a global leader in process intelligence and transformation software, today announced the appointment of Guillaume Bacuvier as Chief Executive Officer. Guillaume will lead ARIS through its next phase of growth as a fully standalone company, accelerating its evolution from a market leader in Process Intelligence into a foundational platform for enterprises deploying and governing Agentic AI. Guillaume brings deep international leadership experience across technology, data, and software-enabled businesses, with a proven track record of scaling global platforms and leading complex organisations. After starting as a strategic consultant at Booz Allen Hamilton, Guillaume spent over a decade at Google, rising to Vice President in EMEA where he built and scaled some of Google’s largest data-driven businesses in Europe and held P&L responsibility across multiple countries. In the last decade, Guillaume has served as CEO of multi-continent, data-centric companies including
I Squared Capital Acquires Ramudden Global, a Leader in Traffic Management and Infrastructure Safety7.1.2026 10:00:00 EET | Press release
I Squared Capital, a leading global infrastructure investment manager, today announced that, through its flagship fund, it has agreed to acquire Ramudden Global, from funds advised by Triton Partners (“Triton”), a leading European mid-market sector-specialist investor. Ramudden Global is a leading international provider of traffic management and infrastructure safety services supporting the maintenance and upgrade of essential transport and utility networks. The company operates more than 190 depots across 13 countries in Europe and North America delivering mission-critical services that help to ensure safety, regulatory compliance and continuity of service across road, utility and broader infrastructure works. This investment underscores I Squared Capital’s commitment to investing in essential, regulated, infrastructure businesses that underpin public safety, mobility and economic activity. Ramudden operates in markets where demand is steady and growing and benefits from deep commerci
RoslinCT and BOOST Pharma Announce Strategic Manufacturing Agreement to Advance Cell Therapy for Infants with Osteogenesis Imperfecta7.1.2026 10:00:00 EET | Press release
RoslinCT, a global contract development and manufacturing organization (CDMO) specializing in advanced cell therapies, and BOOST Pharma, a clinical-stage biotechnology company developing first-in-class cell therapies for rare paediatric skeletal diseases, today announced a strategic manufacturing partnership to support the development of BOOST Pharma’s cell therapy, BT-101, for the treatment of infants with Osteogenesis Imperfecta (OI), also known as brittle bone disease. Under the service agreement, BOOST Pharma has transferred its manufacturing process to RoslinCT’s state-of-the-art facilities in Edinburgh, Scotland. The partnership will progress toward GMP manufacturing of starting materials and clinical drug product, supporting Phase III clinical development of BT-101. The therapy is an allogeneic mesenchymal stem cell (MSC) product designed to address the underlying cause of OI at the earliest stages of life. BOOST Pharma was founded on pioneering science originating from Karolins
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
